Ultragenyx wins first FDA nod for gene therapy targeting rare metabolic disease

The FDA granted accelerated approval to Ultragenyx's gene therapy for an ultra-rare glycogen storage disorder that can trigger dangerous drops in blood sugar. This marks the company's first approved gene therapy. The decision provides a new treatment option for patients with limited existing therapies.